Table 2.
PREVENTT coprimary endpoints from randomisation to 30 days after operation
| Placebo (n=243) | Intravenous iron (n=244) | Iron vs placebo (95% CI, p value) | |
|---|---|---|---|
| Blood transfusion or death | |||
| Combined | 67/237 (28%) | 69/237 (29%) | 1·03 (0·78–1·37, p=0·84) |
| Transfusion | 67/237 (28%) | 68/237 (29%) | .. |
| Death | 2/237 (1%) | 2/237 (1%) | .. |
| Transfusion episodes | |||
| 0 | 170/237 (72%) | 169/237 (71%) | .. |
| 1 | 37/237 (16%) | 49/237 (21%) | .. |
| 2 | 22/237 (9%) | 9/237 (4%) | .. |
| 3 | 5/237 (2%) | 5/237 (2%) | .. |
| 4 | 1/237 (<1%) | 3/237 (1%) | .. |
| 5 | 1/237 (<1%) | 1/237 (<1%) | .. |
| 6 | 1/237 (<1%) | 1/237 (<1%) | .. |
| Mean | 0·47 (0·9) | 0·44 (0·9) | 0·98 (0·68–1·43, p=0·93) |
Data are n/N (%), mean (SD), and risk or rate ratio (95% CI, p value). A transfusion episode is defined as receiving any volume of 1 unit (or part thereof) or more of packed red blood cells or any other blood product. Treatment effect is a risk ratio for the first coprimary endpoint (number of blood transfusions or deaths) and a rate ratio for the second coprimary endpoint; for the second coprimary endpoint, number of blood transfusions is the number of separate transfusions administered.